Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05987956 · ClinicalTrials.gov registry record · Phase 2
Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms
A Phase 2 study, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- Active
- Registry status
- Phase 2
- Development phase
- 600
- Enrollment target
NCT05987956 is a Phase 2 study that is active but no longer recruiting, run by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair. The registered enrollment target is 600 participants.
The verdict
NCT05987956, a Phase 2 study, is active but no longer recruiting, sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 600 participants
- Enrollment target
Study Summary
Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene single nucleotide polymorphisms and ALECENSA - Alectinib side-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes.
Interventions
- DRUG Alectinib - Usual
- DRUG Alectinib - Study
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 600 participants |
| Start Date | 2026-03-18 |
| Est. Completion | 2026-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05987956
The ClinicalTrials.gov registry entry for NCT05987956 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 600 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Alectinib - Usual is the first listed.
NCT05987956 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05987956 about?
NCT05987956 is a clinical study titled "Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms". Explore the relationship between drug target ALK gene single nucleotide polymorphisms and ALECENSA - Alectinib therapeutic-effects in patients with non-small cell lung cancer, based on Oxford precisely sequencing drug targets' genes. Explore the relationship between drug target CYP4503A4 gene singl...
What is the current status of trial NCT05987956?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 600 participants. The study started on 2026-03-18. Estimated completion is 2026-12-28.
What interventions are being tested in trial NCT05987956?
The interventions under investigation include: Alectinib - Usual (DRUG), Alectinib - Study (DRUG).
Who is sponsoring clinical trial NCT05987956?
This trial is sponsored by Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.